Document:

EX-10.8

 Exhibit 10.8 

SHARE EXCHANGE AGREEMENT 

This Share Exchange Agreement (this “Agreement”) is made and entered into as of May 4, 2021 (the
“Agreement Date”), by and among (a) Day One Biopharmaceuticals Holding Company, LLC, a Delaware limited liability company (the “Company”), (b) DOT-1
Therapeutics, Inc., a Delaware corporation (“Subsidiary”) and (c) Millennium Pharmaceuticals, Inc. (the “Stockholder”). 

RECITALS 
 WHEREAS, the
Stockholder is the owner of 9,857,143 shares of Subsidiary’s Series A Preferred Stock, $0.0001 par value per share (referred to hereinafter as the “Series A Preferred” or the “Exchange Shares”).

 WHEREAS, in connection with its initial public offering (the “IPO”), the Company expects to be converted into a
Delaware corporation expected to be called Day One Biopharmaceuticals, Inc. (the “Successor”) pursuant to Section 18-216 of the Delaware Limited Liability Company Act (as amended,
the “LLC Act”) and Section 265 of the Delaware General Corporation Law (as amended, the “DGCL”) (the “Conversion”). 

WHEREAS, in connection with the Conversion and the consummation of the IPO, all outstanding Preferred Units and Common Units in the Company
will be converted into Common Stock of Successor. 
 WHEREAS, the parties desire that the Successor acquire the Exchange Shares from the
Stockholder on the terms and subject to the conditions set forth herein in exchange for the issuance of 2,782,960 shares of the Successor’s Common Stock (subject to proportional adjustment in the event of any stock split, stock dividend, or
other similar event occurring in respect of the Company’s Common Units or Successor’s Common Stock, as applicable prior to the Conversion) (the “Replacement Shares” and such exchange of the Replacement Shares for
the Exchange Shares, the “Share Exchange”). 
 WHEREAS, the Company and Stockholder are the only two stockholders of
Subsidiary as of the date hereof. 
 WHEREAS, as a result of the Share Exchange, Subsidiary will become a wholly-owned subsidiary of the
Successor. 
 WHEREAS, the Share Exchange, together with the Conversion, is intended to qualify as a nontaxable transaction under
Section 351 of the Internal Revenue Code of 1986, as amended. 
 WHEREAS, in connection with Subsidiary’s prior financing
activities, the Subsidiary, the Company and the Stockholder entered into that certain Investors’ Rights Agreement, dated December 16, 2019 (the “Investors Rights Agreement”), that certain Right of First Refusal and Co-sale Agreement, dated December 16, 2019 (the “Co-Sale Agreement”), and that certain Voting Agreement, dated December 16,
2019 (the “Voting Agreement,” and together with the Rights Agreement and the Co-Sale Agreement, the “Subsidiary Financing Documents”). 

WHEREAS, the Voting Agreement may be amended, modified or terminated only by a written instrument executed by Subsidiary and the holders of a
majority of the shares of Subsidiary Common Stock issued or issuable upon conversion of the shares of Subsidiary Preferred Stock held by the Investors (as defined in the Voting Agreement) (the “Voting Agreement Requisite
Majority”). 

  
 1 

 WHEREAS, the Investors Rights Agreement may be amended, modified or terminated only with the
written consent of Subsidiary and the holders of a majority of the shares of Registrable Securities (as defined in the Rights Agreement) then outstanding; provided, however, that the amendment, modification or termination of certain
provisions thereof additionally requires the consent of Stockholder (the “Rights Agreement Requisite Majority”). 

WHEREAS, the Co-Sale Agreement may be amended, modified or terminated only by a written instrument
executed by Subsidiary and the holders of a majority of the shares of Subsidiary Common Stock issued or issuable upon conversion of the then outstanding shares of Subsidiary Preferred Stock held by the Investors (as defined in the Co-Sale Agreement) (the “Co-Sale Agreement Requisite Majority”, and together with the Voting Agreement Requisite Majority and the Rights Agreement
Requisite Majority, the “Subsidiary Requisite Majority”). 
 WHEREAS, concurrently with the Exchange, the Company
and the Stockholder, constituting the Subsidiary Requisite Majority, and Subsidiary wish to terminate the Subsidiary Financing Documents in their entirety. 

WHEREAS, concurrently herewith the parties are entering into a letter agreement regarding that certain Asset Transfer and License Agreement
entered into between Company and Stockholder dated December 16, 2019 (the “ATLA”). 
 NOW, THEREFORE, in
consideration of the foregoing recitals and for other good and valuable consideration, the receipt and adequacy of which the parties acknowledge, the parties, including the Subsidiary Requisite Majority, hereby agree as follows: 

1. AGREEMENT TO EXCHANGE STOCK. 

1.1. Authorization. As of the Closing (as defined below), Successor shall have authorized the issuance to the Stockholder,
pursuant to the terms and conditions of this Agreement, of the full number of Replacement Shares that are to be issued to the Stockholder hereunder. By executing this Agreement, as of the Closing (as defined below), the Company, Subsidiary and the
Stockholder each hereby consent to, or otherwise waive any applicable transfer restrictions in respect of, the transfer of the Exchange Shares from the Stockholder to the Successor in accordance with the Subsidiary Financing Documents,
Subsidiary’s Certificate of Incorporation and Bylaws. 
 1.2. Agreement to Exchange; Full Satisfaction. On the
terms and subject to the conditions set forth herein, at the Closing, the Stockholder shall, and hereby does, transfer, convey and assign all of Stockholder’s right, title and interest in and to all of the Exchange Shares held by the
Stockholder, free and clear of any and all liens or encumbrances, to the Successor, and shall receive in exchange therefor the number and type of newly issued Replacement Shares. The Replacement Shares delivered in accordance with the terms hereof
shall be deemed to have been delivered in full satisfaction of all rights pertaining to the Exchange Shares, and the Stockholder agrees and acknowledges that, upon receipt of the Stockholder’s Replacement Shares, the Stockholder shall have no
further rights as a stockholder of Subsidiary. 
 2. CLOSING. The closing of the Share Exchange shall take place
remotely, and, subject to and conditioned on the fulfillment of the Pricing Condition, shall occur automatically immediately upon the effectiveness of the Conversion and the filing of the initial certificate of incorporation of the Successor with
the Secretary of State of the State of Delaware (the “Closing”). At the Closing, the Exchange Shares shall be cancelled on the books and records of Subsidiary and the Replacement Shares shall be issued to the Stockholder. As
soon as reasonably practicable following the Closing: (a) the Successor shall deliver to the Stockholder an electronic stock certificate representing the Replacement Shares being exchanged electronically; and (b) the Successor shall be
entered into Subsidiary’s stock ledger as the holder of the Exchange Shares and stock certificates shall be issued by Subsidiary to the Successor evidencing the 

  
 2 

 
Successor’s ownership thereof. For the purposes hereof, the “Pricing Condition” shall be fulfilled in the event that the Company and Successor have used commercially
reasonable efforts to ensure that the IPO price per share of the Successor’s common stock has been agreed by the Successor and its IPO underwriters on the same day as the effectiveness of the Conversion and the Closing. 

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby represents and warrants to the Stockholder that the
statements in the following paragraphs of this Section 3 are all true and complete as of the Agreement Date: 
 3.1.
Organization, Good Standing, Power and Qualification. The Company is a limited liability company, duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite limited liability
company power and authority to carry on its business as now conducted and as presently proposed to be conducted.. 
 3.2.
Capitalization. Pursuant to the Company’s Amended and Restated Operating Agreement, as amended (the “Restated Operating Agreement”), the authorized Shares (as defined in the Restated Operating Agreement) of
the Company consist, as of the Agreement Date, of: 
 (a) 17,000,000 Common Shares (as defined in the Restated Operating Agreement),
2,596,073 of which are issued and outstanding, 9,828,498 of which are reserved for issuance upon conversion of the Series A Preferred Shares, and 4,145,441 of which are reserved for issuance upon conversion of the Series B Preferred Shares. The
rights, privileges and preferences of the Common Shares are as stated in the Restated Operating Agreement and as provided by the Delaware Limited Liability Company Act. All of the outstanding Common Shares have been duly authorized, are fully paid
and nonassessable and were issued in compliance with all applicable federal and state securities laws. 
 (b) 13,973,939 Preferred Shares
(as defined in the Restated Operating Agreement), 9,828,498 of which have been designated Series A Preferred Shares, 9,828,498 of which are issued and outstanding, and 4,145,441 of which have been designated Series B Preferred Shares, 4,145,441 of
which are issued and outstanding. The rights, privileges and preferences of the Preferred Shares are as stated in the Restated Operating Agreement and as provided by the LLC Act. 

(c) The Company has reserved 3,838,356 Incentive Shares (as defined in the Restated Operating Agreement) for issuance to officers, managers,
employees and consultants of the Company pursuant to its Incentive Share Plan duly adopted by the Board and approved by the Company’s members. The rights, privileges and preferences of the Incentive Shares are as stated in the Restated
Operating Agreement and as provided by the LLC Act. 
 (d) As a result of the Conversion and the consummation of the IPO, all of the
foregoing Common Shares and Preferred Shares will convert into Common Stock of the Successor. 
 (e) As of immediately prior to the
consummation of the IPO, the Replacement Shares shall represent no less than twelve percent (12%) of the Successor’s Fully Diluted Capitalization. For purposes hereof, “Fully Diluted Capitalization” shall mean the
Successor’s total number of shares of issued and outstanding Common Stock, assuming full conversion or exercise of all convertible and exercisable securities (including Preferred Stock) into Common Stock and including, for this purpose, any
shares then available for issuance but not subject to outstanding grants under the Company’s Incentive Share Plan but excluding, for this purpose, (i) any new equity incentive, employee stock purchase or similar other plans created
in connection with the IPO (or increases to existing plans in connection with the IPO) or (ii) any shares issuable in the IPO. 

  
 3 

 3.3. Due Authorization. All corporate action on the part of the
Company’s directors necessary for (i) the authorization, execution, delivery of and the performance of all obligations of the Company and Successor, as applicable, under this Agreement and (ii) the authorization, issuance, reservation
for issuance and delivery of all of the Replacement Shares pursuant to this Agreement has been taken or will be taken prior to the Closing. This Agreement, when executed and delivered by the Company, will constitute valid and legally binding
obligations of the Company, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or others laws of general application relating to or affecting the enforcement of
creditors’ rights generally, (ii) applicable securities laws limits on indemnification and (iii) the effect of rules of law governing the availability of equitable remedies. 

3.4. Valid Issuance of Stock. 

(a) The Replacement Shares, when paid for and issued as provided in this Agreement, will be duly authorized and validly issued, fully paid and
nonassessable. 
 (b) Assuming the accuracy of the representations made by the Stockholder in Section 4 hereof,
the offer and exchange of the Exchange Shares for the Replacement Shares in accordance with this Agreement are exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “1933
Act”), and the securities registration and qualification requirements of the currently effective provisions of applicable state securities laws. 

4. REPRESENTATIONS, WARRANTIES AND CERTAIN AGREEMENTS OF THE STOCKHOLDER. The Stockholder hereby represents
and warrants to the Company and the Successor, as applicable, and to Subsidiary, that the statements in the following paragraphs of this Section 4 are all true and complete as of the Agreement Date and as of the Closing:

 4.1. Authorization. This Agreement constitutes the Stockholder’s valid and legally binding obligation,
enforceable in accordance with its terms except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors’ rights generally,
(ii) applicable federal or state securities laws limits on indemnification and (iii) the effect of rules of law governing the availability of equitable remedies. The Stockholder has full power and authority to enter into this Agreement.

 4.2. Title to Exchange Shares. The Stockholder has good and marketable title to, and is the legal owner of, the
Exchange Shares to be exchanged by the Stockholder under this Agreement, free and clear of all pledges, liens, security interests and encumbrances. The Stockholder agrees not to sell or transfer, or create or subject to any encumbrance, pledge, lien
or mortgage, any interest in the Exchange Shares prior to the Closing. The Stockholder hereby confirms that, after giving effect to the Closing, the Stockholder will have no interest in or rights to any securities of Subsidiary that are not being
exchanged into securities of the Successor in accordance with the terms of this Agreement, and all of the Stockholder’s interests in and rights to securities of Subsidiary will be so exchanged or extinguished at the Closing in accordance with
the terms of this Agreement. 
 4.3. Exchange for Own Account. The Replacement Shares to be acquired by the Stockholder
hereunder will be acquired for investment for the Stockholder’s own account, not as a nominee or agent, and not with a view to the public resale or distribution thereof within the meaning of the 1933 Act, and the Stockholder has no present
intention of selling, granting any participation in or otherwise distributing the same. 

  
 4 

 4.4. Disclosure of Information. At no time was the Stockholder
presented with or solicited by any publicly issued or circulated newspaper, mail, radio, television or other form of general advertising or solicitation in connection with the offer, sale, purchase or exchange of the Replacement Shares. The
Stockholder has received or has had full access to all the information that the Stockholder considers necessary or appropriate to make an informed investment decision with respect to the Replacement Shares to be acquired by the Stockholder under
this Agreement. The Stockholder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Replacement Shares and to obtain additional information necessary to
verify any information furnished to the Stockholder or to which the Stockholder had access, and such answers and additional information have been received by the Stockholder to the Stockholder’s satisfaction. The foregoing, however, does not in
any way limit or modify the representations and warranties made by the Company in Section 3. 
 4.5. Investment
Experience. The Stockholder understands that the acquisition of the Replacement Shares involves substantial risk. The Stockholder (i) has experience as an investor in securities of companies in the development stage and acknowledges
that the Stockholder is able to fend for itself, can bear the economic risk of the Stockholder’s investment in the Replacement Shares, and has such knowledge and experience in financial or business matters that the Stockholder is capable of
evaluating the merits and risks of this investment in the Replacement Shares and protecting the Stockholder’s own interests in connection with this investment, and/or (ii) has a preexisting personal or business relationship with the
Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Stockholder to be aware of the character, business acumen and financial circumstances of such persons. The Stockholder’s current
permanent residence is as set forth on signature pages hereto. 
 4.6. Accredited Investor. The Stockholder: is an
“accredited investor” within the meaning of Rule 501 of Regulation D promulgated by the United States Securities and Exchange Commission (“SEC”) under the 1933 Act. 

4.7. Restricted Securities. The Stockholder understands that the Replacement Shares are characterized as “restricted
securities” under the 1933 Act inasmuch as they are being acquired from the Successor in a transaction not involving a public offering and that under the 1933 Act and applicable regulations thereunder such securities may be resold without
registration under the 1933 Act only in certain limited circumstances. In this connection, the Stockholder represents that the Stockholder is familiar with Rule 144 promulgated by the SEC under the 1933 Act and understands the resale limitations
imposed by Rule 144 and by the 1933 Act. The Stockholder understands that the Successor is under no obligation to register any of the securities sold hereunder. The Stockholder understands that no public market now exists for any of the Replacement
Shares and that none of the Company, Subsidiary or any of their respective officers, directors, employees or agents has made any assurances that a public market will ever exist for the Replacement Shares. 

4.8. Further Limitations on Disposition. Without in any way limiting the representations set forth above, the Stockholder
further agrees not to make any disposition of all or any portion of the Replacement Shares unless and until: 
 (a) there is then in effect
a registration statement under the 1933 Act covering such proposed disposition and such disposition is made pursuant to such registration statement; 

(b) following the IPO, the transfer is made pursuant to SEC Rule 144; or 

(c) the Stockholder shall have notified the Successor of the proposed disposition and shall have furnished the Successor with a statement of
the circumstances surrounding the proposed disposition, and, at the expense of the Stockholder or its transferee, with an opinion of counsel, satisfactory to the Successor in its sole discretion, that such disposition will not require registration
of such securities under the 1933 Act or any state securities laws. 

  
 5 

 4.9. Legends. It is understood that the certificates evidencing the
Replacement Shares will bear legends as required by United States federal or state securities laws. 
 4.10. Compliance with
Law. The Stockholder has satisfied itself as to the full observance of the laws of any jurisdiction applicable to the Stockholder in connection with any invitation to subscribe for, or the Stockholder’s acquisition of, the Replacement
Shares or any use of this Agreement, including (i) the legal requirements within each jurisdiction applicable to the Stockholder for the acquisition of the Replacement Shares, (ii) any foreign exchange restrictions applicable to such
acquisition, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, exchange or other transfer of
any Replacement Shares. The Stockholder’s subscription and payment for the Replacement Shares will not violate any applicable securities or other laws of any jurisdiction applicable to the Stockholder and no consent or approval of any
governmental entity is required for the Stockholder to enter into this Agreement and consummate the transactions contemplated herein, including, without limitation, the commencement of the Share Exchange, the Closing and the Stockholder’s
subscription and payment for the Replacement Shares. 
 4.11. Tax Matters. The Stockholder has reviewed, or has had the
opportunity to review, with the Stockholder’s own tax advisors, the United States federal, state, local and foreign tax consequences of the Stockholder’s acquisition of the Replacement Shares and of the transactions contemplated by this
Agreement. The Stockholder is relying solely on such advisors with respect to tax consequences and not on any statements or representations of the Company or any of the Company’s officers, directors, employees or agents other than the
representations and warranties set forth in Section 3 hereof. The Stockholder understands that the Stockholder (and not the Company or the Successor) shall be responsible for the Stockholder’s own tax liability that may arise as a result
of the Stockholder’s acquisition of the Replacement Shares or the transactions contemplated by this Agreement. 
 5. ADDITIONAL
AGREEMENTS. 
 5.1. Termination of Agreements. The Company, Subsidiary and the Stockholder hereby agree that the
Subsidiary Financing Documents are hereby terminated effective as of the Closing, and shall be of no further force or effect. Furthermore, Subsidiary and the Stockholder agree that, other than the ATLA (and any side letters associated therewith) and
this Agreement, any and all other agreements between the Stockholder and Subsidiary are hereby terminated and cancelled and shall be null and void from and after the date hereof. 

5.2. Frustration of Purpose. In the event that the Conversion and the Exchange have occurred but the IPO is not
consummated prior to the Outside Date (as defined below), the Company, Subsidiary, and Successor shall, upon the Stockholder’s request, use reasonable best efforts and cooperate in good faith with the Stockholder to unwind the transactions
contemplated hereby and restore the Stockholder’s rights to be as they were on the date hereof. 
 5.3. RELEASE.

 (a) EFFECTIVE UPON THE CLOSING, THE STOCKHOLDER, ON BEHALF OF ITSELF AND EACH OF ITS AFFILIATES UNDER COMMON CONTROL WITH THE STOCKHOLDER
(EACH A “RELEASING PARTY”), HEREBY UNCONDITIONALLY AND IRREVOCABLY RELEASES, WAIVES AND FOREVER DISCHARGES THE COMPANY (INCLUDING AS THE SUCCESSOR), SUBSIDIARY, EACH OF THEIR RESPECTIVE AFFILIATES, AND ALL OF THEIR RESPECTIVE
PAST AND PRESENT DIRECTORS, OFFICERS, MANAGERS, EMPLOYEES, MEMBERS, AND 

  
 6 

 
STOCKHOLDERS (COLLECTIVELY, THE “RELEASED PARTIES”), FROM ANY AND ALL RIGHTS, ACTIONS, CAUSES OF ACTION, SUITS, DEBTS, SUMS OF MONEY, ACCOUNTS, RECKONINGS, DAMAGES,
JUDGMENTS, EXECUTIONS, LOSSES, CLAIMS AND DEMANDS WHATSOEVER, OF WHATEVER KIND OR NATURE, UNDER ANY CONTRACT, AGREEMENT, FEDERAL, STATE OR LOCAL STATUTE, ORDINANCE OR UNDER COMMON LAW OR OTHERWISE, THAT ANY RELEASING PARTY EVER HAD, HAS NOW OR MAY
HAVE IN THE FUTURE (“CLAIMS”) AGAINST ANY OF THE RELEASED PARTIES ARISING SOLELY FROM (A) THE STOCKHOLDER’S OWNERSHIP OF THE EXCHANGE SHARES PRIOR TO THE CLOSING OR (B) ANY OTHER AGREEMENT OR TRANSACTION
BETWEEN THE STOCKHOLDER, ON ONE HAND, AND THE SUBSIDIARY AND/OR THE COMPANY (INCLUDING AS THE SUCCESSOR), ON THE OTHER HAND, ENTERED INTO PRIOR TO THE CLOSING, IN EACH CASE OTHER THAN THE ATLA (AND ANY SIDE LETTERS ASSOCIATED THEREWITH) AND THIS
AGREEMENT. 
 (b) The Stockholder hereby acknowledges that the Stockholder is aware of the principle that a general release does not extend
to claims that the releasor does not know or suspect to exist in his or her favor at the time of executing the release, which, if known by him or her, must have materially affected his or her settlement with the releasee. With knowledge of this
principle, the Stockholder hereby agrees to expressly waive any rights v may have to that effect. 
 (c) The Company does not intend that
the Stockholder release claims that the Stockholder may not release as a matter of law, including but not limited to claims for indemnity, or any claims for enforcement of this Agreement. To the fullest extent permitted by law, any dispute regarding
the scope of this general release shall be determined in accordance with Section 6.5 below. 
 5.4.
“Market Stand-off” Agreement. Stockholder hereby agrees that, during the period commencing on the date of the final prospectus relating to the
registration by the Successor of shares of its Common Stock or any other equity securities under the 1933 Act on a registration statement on Form S-1, and ending on the date specified by the Successor and the
managing underwriter (such period not to exceed one hundred eighty (180) days), Stockholder will not, without the prior written consent of the Successor or the managing underwriter: 

(a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right, or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock, held
immediately before the effective date of the registration statement for such offering; or 
 (b) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Common Stock or
other securities, in cash, or otherwise. 
 The foregoing provisions of this Section 5.3 shall only apply to the IPO and shall not apply to the sale of
any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Stockholder’s only if all officers, directors, and stockholders individually owning more than 1% of the Successor’s outstanding Common Stock
(after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are similarly bound. For purposes of this Section 5.3, the term “Successor” shall include any wholly-owned subsidiary of the Successor into which
the Successor merges or 

  
 7 

 
consolidates. In order to enforce the foregoing covenant, the Successor shall have the right to place restrictive legends on the certificate or instrument representing the shares subject to this
Section 5.3 and to impose stop transfer instructions with respect to such shares until the end of such period. The underwriters in connection with such registration are intended third-party beneficiaries
of this Section 5.3 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Stockholder further agrees to execute such agreements as may be reasonably requested by the underwriters in
connection with such registration that are consistent with this Section 5.4 or that are necessary to give further effect thereto. 

5.5. Reports Under Exchange Act. To the extent and during the time period required to make available to the Stockholder
the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit the Stockholder to sell the Replacement Shares to the public without registration following the IPO, the Successor shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Successor for the IPO; 
 (b) use commercially reasonable efforts to file with
the SEC in a timely manner all reports and other documents required of the Successor under the 1933 Act and the Securities Exchange Act of 1934 (the “Exchange Act”) (at any time after the Successor has become subject to such
reporting requirements); 
 (c) furnish to the Stockholder, so long as the Stockholder owns any Replacement Shares, forthwith upon request
(i) to the extent accurate, a written statement by the Successor that it has complied with the reporting requirements of SEC Rule 144 (at any time after 90 days after the effective date of the registration statement filed by the Successor for
the IPO), the 1933 Act, and the Exchange Act (at any time after the Successor has become subject to such reporting requirements); and (ii) such other information as may be reasonably requested in availing the Stockholder of any rule or
regulation of the SEC that permits the selling of any such securities without registration (at any time after the Successor has become subject to the reporting requirements under the Exchange Act); and 

(d) upon the request of the Stockholder, cooperate with the Stockholder and the Successor’s transfer agent to promptly remove legends
from the Replacement Shares when legally able to do so and transfer the Replacement Shares to a brokerage account of the Stockholder. 

6. GENERAL PROVISIONS. 

6.1. Termination. This Agreement may be terminated solely with the written consent of the Stockholder and the Company (or
the Successor, if applicable); provided, however, that in the event that the Closing has not occurred on or prior to August 15, 2021 (the “Outside Date”), this Agreement may be terminated by either the
Company (or the Successor, if applicable) or the Stockholder by delivery of written notice to the other parties hereto, unless such failure of the Closing to occur has been caused primarily by any breach of this Agreement by the party seeking to so
terminate this Agreement. 
 6.2. Survival of Warranties. The representations, warranties and covenants of the Company,
Subsidiary and Stockholder contained in this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of Stockholder
or the Company, as the case may be. 

  
 8 

 6.3. Successors and Assigns. Except as otherwise provided in this
Agreement, this Agreement, and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators and legal representatives. This Agreement,
and the rights and obligations of a party hereunder, may not be assigned by such party without the prior written consent of the other parties hereto. Notwithstanding anything to the contrary herein, this Agreement shall be deemed automatically (and
without the need for any consent or action) assigned by the Company to the Successor upon the Conversion and the Successor shall succeed to all of the Company rights and obligations hereunder. 

6.4. Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware,
without regard to its conflict of laws principles. 
 6.5. Dispute Resolution. The parties (a) hereby
irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out
of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware,
and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is
exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be
enforced in or by such court. 
 6.6. Counterparts. This Agreement may be executed in any number of counterparts, each
of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. Any signature page hereto delivered by e-mail (including in portable
document format (pdf), as a joint photographic experts group (jpg) file, or otherwise) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto. 

6.7. Titles and Headings. The titles, captions and headings of this Agreement are included for ease of reference only and
will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references herein to “sections” and “exhibits” will mean “sections” and “exhibits” to this Agreement.

 6.8. Notices. Any and all notices required or permitted to be given to a party pursuant to the provisions of this
Agreement will be in writing and will be effective and deemed given on the earliest of the following: (i) at the time of personal delivery, if delivery is in person; (ii) at the time of transmission by
e-mail, addressed to the other party at its e-mail address specified herein, provided that in the case of transmission received after 5:00 p.m. at the recipient’s
location or on a day that is not a business day at the recipient’s location, notice will be deemed given on the next business day at the recipient’s location; (iii) one business day after deposit with an express courier for delivery
on the next business day within the United States, or two business days after such deposit for delivery no later than the second business day outside the United States, with proof of delivery from the courier requested; or (iv) five business
days after deposit in the United States mail by certified mail, return receipt requested, for delivery within the United States. 
 All notices for delivery
outside the United States will be sent by e-mail or by internationally recognized express courier. All notices not delivered personally or by e-mail will be sent with
postage and/or other charges prepaid. All notices will be properly addressed to the party to be notified at the address or e-mail address as follows, or at such other address or
e-mail address as such other party may designate by notice given in accordance with this Section 7.6, as follows; 

  
 9 

 (a) if to the Stockholder, at the address set forth opposite the Stockholder’s name on
the Stockholder’s signature page hereto; 
 (b) if to the Company (or the Successor, if applicable), marked “Attention: CEO”
at the address set forth on the Company’s signature page hereto; 
 (c) if to Subsidiary, marked “Attention: CEO” at the
address set forth on Subsidiary’s signature page hereto. 
 6.9. Amendments and Waivers. Any term of this Agreement
may be amended only with the written consent of the Company (or the Successor, if applicable) and the Stockholder. Any amendment effected in accordance with this Section 6.9 shall be binding upon the parties hereto. Any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively) by the Company and the Stockholder. No delay or failure to require performance of any provision of this Agreement shall constitute a waiver of
that provision as to that or any other instance. No waiver granted under this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein, nor shall it constitute the waiver of any
performance other than the actual performance specifically waived. 
 6.10. Severability. If any provision of this
Agreement is determined by any court or arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such
clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not
enforceable) never been contained in this Agreement. Notwithstanding the foregoing, if the value of this Agreement based upon the substantial benefit of the bargain for any party is materially impaired, which determination as made by the presiding
court or arbitrator of competent jurisdiction shall be binding, then the parties agree to substitute such provision(s) through good faith negotiations with a valid, legal and enforceable provision that will achieve, to the extent possible, the
economic, business and other purposes of such invalid, illegal or unenforceable provision. 
 6.11. Entire Agreement.
This Agreement and the documents referred to herein, together with all the Exhibits hereto, constitute the entire agreement and understanding of the parties with respect to the subject matter of this Agreement, and supersede any and all prior and
contemporaneous understandings and agreements, whether oral or written, between or among the parties hereto with respect to the specific subject matter hereof. 

6.12. Further Assurances. The parties agree to execute such further documents and instruments and to take such further
actions as may be reasonably necessary to carry out the purposes and intent of this Agreement. 
 6.13. Third Parties.
Nothing in this Agreement, express or implied, is intended to confer upon any person, other than the parties hereto and their successors and assigns, any rights or remedies under or by reason of this Agreement. 

[Signature page follows] 

  
 10 

 IN WITNESS WHEREOF, the parties hereto have executed this Share Exchange Agreement as
of the date first written above. 
 COMPANY: 
 DAY
ONE BIOPHARMACEUTICALS 
 HOLDING COMPANY, LLC. 
  

			
	By:	 	 /s/ Jeremy Bender

	Name:	 	Jeremy Bender
	Title:	 	Chief Executive Officer

 Address: 
 Email: 

SUBSIDIARY: 
 DOT
THERAPEUTICS-1, INC. 
  

			
	By:	 	 /s/ Jeremy Bender

	Name:	 	Jeremy Bender
	Title:	 	Chief Executive Officer

 Address: 
 Email: 

[SIGNATURE PAGE TO SHARE EXCHANGE AGREEMENT]

 IN WITNESS WHEREOF, the parties hereto have executed this Share Exchange Agreement as
of the date first written above. 
  

			
	STOCKHOLDER:
	
	MILLENNIUM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Michael Martin

	Name: Michael Martin
	Title: President, Takeda Ventures, Inc.

  

	Address:	 9625 Towne Center Drive 

	 	 San Diego, CA 92121 

Email: 
 [SIGNATURE
PAGE TO SHARE EXCHANGE AGREEMENT]Document

EXHIBIT 10.1
PERFORMANCE UNIT GRANT 
AWARD AGREEMENT

    This AGREEMENT (“Agreement”) is made as of February 17, 2021, by and between Service Corporation International, a Texas corporation (the “Company”), and               (the “Employee”).
    WHEREAS, the Compensation Committee (“Compensation Committee”) of the Board of Directors of the Company has determined that it is to the advantage and interest of the Company to grant to the Employee the performance units grant provided for herein in consideration of services provided by the Employee and to provide focus on the longer-term success of the Company.
    NOW, THEREFORE, the Company and the Employee hereby agree as follows:
1.Grant of Award.  
a.Pursuant to the Company’s Amended and Restated 2016 Equity Incentive Plan (“Plan”), the Employee is hereby granted as of January 1, 2021, a Performance Unit Grant Award (the “Award”), subject to the terms and conditions set forth below, with respect to              performance units (“Units”).  
b.Each Unit shall have a value equal to the value of one share of the Company’s common stock. 
c.If a dividend is paid on the Company’s common stock during the Performance Cycle, the number of Units listed above shall be increased on the dividend payment date by (i) multiplying the per share dividend amount by the number of Units credited under this Agreement on the dividend payment date, and (ii) dividing that amount by the value of a share of the Company’s common stock on the dividend payment date. 
d.If the Units covered by this Award become vested in accordance with Section 2 below, the Employee will be entitled to receive, net of applicable withholding or applicable social security taxes, a cash payment representing the product of (i) the value of a share of the Company’s common stock on the date of approval of the payment by the Compensation Committee (which value shall be an average of the closing price of Company common stock over the five trading days up to and including the date of approval), multiplied by (ii) the number of Units vested, multiplied by (iii) the Performance Settlement Factor as determined using Exhibit A, attached hereto and made a part of this Agreement.  
e.If the Award becomes vested and payable, the Award will be paid to the Employee as soon as practicable after the end of the Performance Cycle, but no later than March 15, 2024.
2.Vesting.  If the Employee is employed by the Company (or any Affiliate thereof) continuously during the Performance Cycle and through the payment date for the Award, as described in Section 1(e) above (the “Payment Date”), the Award will vest 100% on the Payment 

Date.  Except as provided below, this Award shall terminate, and all of the Employee’s rights hereunder shall be forfeited, if the Employee is not employed on the Payment Date.
a.Death, Disability and Termination by the Company without Cause.  In the event of the termination of the Employee’s employment with the Company (or any Affiliate thereof) prior to the Payment Date due to the Employee’s death, Disability or termination by the Company (or an Affiliate thereof) without cause (as that term is defined in Employee’s employment agreement with an Affiliate of Company, or if none, as determined by the Company in its reasonable discretion), a pro-rata portion of the Award will vest, as determined in accordance with the following calculation:  The number of Units under the Award to be vested is determined by the number of active months of employment by the Employee during the Performance Cycle divided by 36 (which is the number of months in the “Performance Cycle” as set forth in Exhibit A).
b.Retirement.  In the event of the termination of the Employee’s employment with the Company (or any Affiliate thereof) prior to the to the Payment Date due to the Employee’s retirement on or after attainment of age 60 with ten (10) years of service, or retirement on or after attainment of age 55 with twenty (20) years of service, the Award will vest, if the Compensation Committee, in its sole discretion, acting by meeting or unanimous consent occurring prior to the effective date of the Employee’s retirement, causes the Award to vest, in which event the Award will fully vest without prorating regardless of the number of months remaining in the Performance Cycle.
c.Change of Control.  In the event of a Change of Control of the Company during the Performance Cycle, the Award will be fully vested and paid at the Target amount set forth on Exhibit A.  Any payment under this Section 2(c) shall be made on the date Change in Control occurs.
Notwithstanding any provision of this Agreement or any other agreement between the Employee and the Company, in the event of a termination of the Employee’s employment with the Company (or any Affiliate thereof) by the Company for cause (as described above), or if the Employee terminates his or her employment with the Company (or any Affiliate thereof) for any reason, any unpaid Award shall be forfeited in its entirety and will not be paid. 
3.Transfer Restrictions.  This Award is non-transferable other than by will or by the laws of descent and distribution, and may not otherwise be assigned, pledged or hypothecated and shall not be subject to execution, attachment or similar process.  Upon any attempt by the Employee (or the Employee’s successor in interest after the Employee’s death) to effect any such disposition, or upon the levy of any such process, the Award may immediately become null and void, at the discretion of the Compensation Committee.
4.Tax.  The Employee will pay any and all Federal, state or local income tax and all associated employment taxes (FICA) when the Award is paid.
5.Miscellaneous.  This Agreement (i) shall be binding upon and inure to the benefit of any successor of the Company, (ii) shall be governed by the laws of the State of Texas and any applicable laws of the United States, and (iii) may not be amended without the written consent of both the Company and the Employee.  No contract or right of employment shall be implied by this Agreement. 

6.Incorporation of Plan Provisions. This Award and the terms and conditions herein set forth are subject in all respects to the terms and conditions of the Plan, which shall be controlling and are incorporated herein by reference.  Capitalized terms not otherwise defined herein (inclusive of Exhibit A) shall have the meanings set forth for such terms in the Plan.
7.IRC §409A Compliance.  Notwithstanding the applicable provisions of this Agreement regarding timing of distribution of payments, the following special rules shall apply in order for this Agreement to comply with IRC §409A: (i) to the extent any distribution is to a “specified employee” (as defined under IRC §409A) and to the extent such applicable provisions of IRC §409A require a delay of such distributions by a six month period after the date of such Employee’s separation of service with the Company, the provisions of this Agreement shall be construed and interpreted as requiring a six month delay in the commencement of such distributions thereunder.
To the extent of any compliance issues under IRC §409A, the Agreement shall be construed in such a manner so as to comply with the requirements of such provision so as to avoid any adverse tax consequences to the Employee.
8.Payment Limitations.  Notwithstanding anything herein to the contrary, the following limitations shall apply to any calculation of payments under this Agreement:
a.If the Company’s TSR for the Performance Cycle is negative, the Performance Settlement Factor used to calculate the Award payment shall not exceed the Target amount set forth in Section B of Exhibit A.  
b.If the Company’s TSR ranking for the Performance Cycle is below the 25th percentile of the TSR of the peers in the Comparator Group, then no payment shall be made under this Agreement.
c.If the Company’s Annualized ROE for the Performance Cycle is less than the average of the median ROE for the S&P midcap 400 companies for each fiscal year during the Performance Cycle, then the amount that would otherwise have been paid under Section 1(d) of this Agreement shall be reduced by twenty-five percent (25%).  
9.Clawback.  If (i) the Employee is a Company officer at or above the level of Vice President at the date of this Agreement, and (ii) it is determined that the Employee has engaged in fraud that causes, in whole or in part, a material adverse restatement of the Company’s financial statements, then any unpaid Award shall be forfeited in its entirety.  In addition, if (A) an Award has been paid under this Agreement prior to the time of such determination, and (B) the payment occurred at any time after the ending date of the period covered by the incorrect financial statements, then the Employee must repay the Company the entire amount of his or her Award payment.  Any determination by the Board of Directors with respect to the foregoing shall be final, subject however to the right of the Employee to contest such determination in any court of competent jurisdiction.  The Company agrees to pay promptly as incurred all legal fees and expenses which the Employee may reasonably incur as a result of any such contest; provided however, if the Employee does not prevail in such contest, the Employee will reimburse the Company for all such legal fees and expenses.  As used herein, the term “fraud” shall mean the act of knowingly making a false representation of a material fact with the intent to deceive.

10.Binding Effect.  This Agreement shall be effective only if executed by the Company (by manual, electronic, typed, stamped or facsimile signature), recorded as a performance unit grant in the minutes of the committee administering the Plan and manually signed by the Employee.  This Agreement shall be binding upon and inure to the benefit of any successors to the Company and all persons lawfully claiming under the Employee.
[Signature Page Attached]
    IN WITNESS HEREOF, the Employee and the Company have executed this Performance Unit Grant Award as of the day and year first above written.

EMPLOYEE                                                     Service Corporation International
                                                                                    /s/ Gregory T. Sangalis
_________________________________       _________________________________
[Signature]                                                        Name:  Gregory T. Sangalis
                                                                         Title:     Senior Vice President
        General Counsel and Secretary

Exhibit A

Calculation of Performance Settlement Factor

The Performance Settlement Factor used to determine the amount payable under the Performance Unit Award described in the attached Performance Unit Grant Award Agreement, dated as of February 17, 2021, between Service Corporation International, a Texas corporation (the “Company” or “SCI”), and all of its Affiliates and the Employee, shall be calculated as provided in this Exhibit A.
A.Definitions.  For purposes of this Award, the following definitions will control:
•“Adjusted Average Equity” means Adjusted Prior Year Equity, plus Adjusted Current Year Equity, divided by 2. An adjusting entry in excess of $50 million may be carried forward to avoid distortion in the Return on Equity calculation during each year of the Performance Cycle.
•“Adjusted Current Year Equity” means Total Stockholder Equity, less accumulated Other Comprehensive Income as set forth in the Company’s Consolidated Balance Sheet, and excluding non-recurring items in both the current and prior fiscal years. 
•“Adjusted Prior Year Equity” means Total Stockholder Equity, as set forth in the Company’s Consolidated Balance Sheet, and excluding non-recurring items in the prior fiscal year.
•“Adjusted Net Income from Continuing Operations” means the Company’s consolidated net income from continuing operations, as determined under U.S. Generally Accepted Accounting Principles, for the fiscal year, as reported in the Company’s financial statements utilizing the forecasted normalized effective tax rate, which may be adjusted to exclude the following items:
1.Significant litigation costs and/or settlements.
2.Special accounting, tax or restructuring charges.
3.The cumulative effect of changes in accounting or tax principles.  
4.An extraordinary gain or loss or correction of an error.
5.All gains, losses or impairment charges recorded in association with the sale or potential sale of a business and/or real estate or any impairment(s) related to the evaluation of goodwill, intangible assets, long-lived assets or loss contracts.
6.Charges relating to the opening, closing, or relocation of subsidiaries or other overhead centers. 
7.The gain or loss associated with the early extinguishment of debt or other debt restructuring charges.

8.Accounting and/or tax charges relating to acquisitions and dispositions, system conversions and/or implementations, settlement or termination of pension obligations, and transitions or terminations of major vendors and/or suppliers of the Company.
9.Currency gains or losses. 

•“Annualized ROE” means the product of (i) the sum of the Return on Equity for each fiscal year during the Performance Cycle, divided by (ii) three. 
•“Award” is a grant of Units as approved by the Compensation Committee.  The number Units subject to the Award shall be increased, as provided in Section 1(c) of the Agreement, to reflect the deemed reinvestment of dividends during the Performance Cycle.
•“Comparator Group” is defined as the publicly traded U.S. companies which are included in the reference group as documented in the 2021 Compensation Committee’s records and which are in existence at the end of the Performance Cycle.
•“Compensation Committee” means the Compensation Committee of the Board of Directors of Service Corporation International.
•“IRC §409A” means Section 409A of the Internal Revenue Code of 1986, as amended.
•“National Exchange” is defined as the New York Stock Exchange (NYSE) or the National Association of Stock Dealers and Quotes (NASDAQ).
•“Plan Administrator” is Compensation Committee, which may delegate certain elements of administrative responsibility to the Company’s CEO or appropriate members of his staff.  Any performance goals, performance standards and award determinations must be approved by the Compensation Committee.
•“Performance Cycle” is defined as the three-year period beginning December 31, 2020 and ending December 31, 2023.
•“Performance Settlement Factor” is the applicable percentage set forth in Section B below, which shall be applied to the number of vested units based on the Company’s relative TSR ranking within the Comparator Group, as interpolated.  
•“Return on Equity” shall be calculated for each fiscal year during the Performance Cycle by dividing (i) the Company’s Adjusted Net Income from Continuing Operations, for the fiscal year, by (ii) the Adjusted Average Equity for such fiscal year.  

•“Total Shareholder Return” (TSR) is defined as the rate of return reflecting stock price appreciation plus reinvestment of dividends over the Performance Cycle.  Specifically, TSR will be calculated using the following provisions: $100 invested in SCI stock on the first day of the Performance Cycle, with dividends reinvested on each applicable payment date, compared to $100 invested in each of the peer companies in the Comparator Group, with dividend reinvestment on each applicable payment date during the same period.  For purposes of this calculation, any determination of reinvested dividends shall be calculated as the sum of the total dividends paid on one share of stock during the Performance Cycle, assuming reinvestment of such dividends in such stock (based on the closing stock price of such stock on the applicable dividend payment date).  For the avoidance of doubt, it is intended that the foregoing calculation of reinvested dividend amount shall take into account not only the reinvestment of dividends in a share of stock but also capital appreciation or depreciation in the shares of stock deemed acquired by such reinvestment.
•“Unit” is a performance unit which shall have a value equal to the closing price of a share of the Company’s common stock.  
B.Performance Unit Awards Settlement Criteria:

									
	SCI Weighted Average Total Shareholder Return Ranking Relative to Comparator Group at End of Performance Cycle	Ranking	% of Target Award Paid as Incentive
(Performance Settlement Factor)

	Maximum	75th% or greater
	200%
		70th%ile
	180%
		65th%ile
	160%
		60th%ile
	140%
		55th%ile
	120%
	Target	50th%ile
	100%
		45th%ile
	85%
		40th%ile
	70%
		35th%ile
	55%
		30th%ile
	40%
	Threshold	25th%ile
	25%
	Below Threshold	Less than 25th%ile 
	0%

•Calculation of awards for performance levels between Target and Maximum, or Threshold and Target will be calculated using straight-line interpolation.

•If mergers and acquisitions result in a reduction in the number of peer group companies during the cycle, these percentile rankings will reflect the Comparator Group companies still intact at the end of the Performance Cycle.
•As provided in Section 8(a) of the Agreement, in the event SCI’s TSR is negative at the end of the Performance Cycle, no payment hereunder will exceed the Target in the schedule above.
•As provided in Section 8(c) of the Agreement, in the event SCI’s Annualized ROE for the Performance Cycle is less than the average of the median ROE for the S&P midcap 400 companies for each fiscal year during the Performance Cycle, as calculated at the end of the Performance Cycle, the amount payable in settlement of the Units shall be reduced by twenty-five percent (25%).
•The Compensation Committee shall have the reasonable discretion to interpret or construe ambiguous, unclear or implied terms applicable to this Agreement, and to make any findings of fact necessary to make a calculation or determination hereunder. 
•A decision made in good faith by the Compensation Committee shall govern and be binding in the event of any dispute regarding a method of calculation of performance or a determination of vesting or forfeiture in connection with the Award or this Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]